BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7696780)

  • 1. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.
    Harris MG; Benfield P
    Drugs Aging; 1995 Jan; 6(1):64-84. PubMed ID: 7696780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
    Benfield P; Heel RC; Lewis SP
    Drugs; 1986 Dec; 32(6):481-508. PubMed ID: 2878798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.
    Vandel S; Bertschy G; Baumann P; Bouquet S; Bonin B; Francois T; Sechter D; Bizouard P
    Pharmacol Res; 1995 Jun; 31(6):347-53. PubMed ID: 8685072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tianeptine: a review of its use in depressive disorders.
    Wagstaff AJ; Ormrod D; Spencer CM
    CNS Drugs; 2001; 15(3):231-59. PubMed ID: 11463130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents].
    Bertschy G; Vandel S; Perault MC
    Therapie; 1994; 49(6):509-12. PubMed ID: 7878612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants.
    Souêtre E; Martin P; Lozet H; Monteban H
    Int Clin Psychopharmacol; 1996 Mar; 11(1):45-52. PubMed ID: 8732313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the efficacy of traditional antidepressive agents and the new generation of antidepressives in the treatment of depressive disorders].
    Cvjetković-Bosnjak M; Knezević A; Soldatović-Stajić B
    Med Pregl; 1999; 52(3-5):108-11. PubMed ID: 10518394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fluoxetine: an update of its use in major depressive disorder in adults].
    Gourion D; Perrin E; Quintin P
    Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine: a review of its use in major depression.
    Holm KJ; Markham A
    Drugs; 1999 Apr; 57(4):607-31. PubMed ID: 10235695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Milnacipran. A review of its use in depression.
    Spencer CM; Wilde MI
    Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants.
    Pacher P; Ungvari Z; Kecskemeti V; Furst S
    Curr Med Chem; 1998 Oct; 5(5):381-90. PubMed ID: 9756980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricyclic antidepressant plasma levels after fluoxetine addition.
    Vandel S; Bertschy G; Bonin B; Nezelof S; François TH; Vandel B; Sechter D; Bizouard P
    Neuropsychobiology; 1992; 25(4):202-7. PubMed ID: 1454161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
    Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
    Wilde MI; Plosker GL; Benfield P
    Drugs; 1993 Nov; 46(5):895-924. PubMed ID: 7507038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of antidepressants.
    Kasper S; Fuger J; Möller HJ
    Drugs; 1992; 43 Suppl 2():11-22; discussion 22-3. PubMed ID: 1378369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine: a five-year review.
    Stokes PE
    Clin Ther; 1993; 15(2):216-43; discussion 215. PubMed ID: 8519034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of new treatments for depression.
    Montgomery SA
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):3-6. PubMed ID: 3882678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.